Mercaptopurine medication monitoring system for children with acute lymphatic leukemia
The invention relates to a mercaptopurine medication monitoring system for children with acute lymphatic leukemia. The treatment of 6-mercaptopurine is an important therapeutic drug for ALL children, but obvious hematotoxicity and hepatotoxicity can occur in the treatment process of 6-mercaptopurine...
Gespeichert in:
Hauptverfasser: | , , , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention relates to a mercaptopurine medication monitoring system for children with acute lymphatic leukemia. The treatment of 6-mercaptopurine is an important therapeutic drug for ALL children, but obvious hematotoxicity and hepatotoxicity can occur in the treatment process of 6-mercaptopurine. In order to ensure the clinical curative effect of 6-MP and reduce the incidence rate of leukopenia and hepatotoxicity, the invention provides a mercaptopurine individualized treatment guidance method for children with acute lymphatic leukemia based on gene polymorphism and blood concentration monitoring and application. Based on the 6-MP metabolism related markers and the 6-TGN content in blood, a medication guidance system for Chinese acute lymphatic leukemia patients is established, and compared with a traditional scheme, the method disclosed by the invention is beneficial to realizing precise treatment.
本发明涉及一种急性淋巴白血病患儿巯嘌呤用药监测系统。6-巯基嘌呤治疗是ALL患儿的重要治疗药物,但该部分治疗过程会发生明显的血液毒性和肝毒性。为了确保6-MP的临床疗效,降低白细胞减少及肝毒性发生率,本发明提供了一 |
---|